Prävalenz und Verlauf unterschiedlicher Ätiologien bei Patienten mit klinischem Verdacht auf Kardiomyopathie in den Jahren 2000 – 2008

Ziel der Arbeit ist die Untersuchung der Prävalenz viraler bzw. entzündlicher Ätiologien, davon abhängig den Krankheitsverlauf bei Patienten mit klinischem Verdacht auf Kardiomyopathie und den Effekt einer spezifischen, kausal orientierten Therapie. Grundlage dazu bilden Daten von 1.710 Patienten, d...

Full description

Saved in:
Bibliographic Details
Main Author: van Gellecom, Joachim
Contributors: Pankuweit, Sabine (Dr.) (Thesis advisor)
Format: Dissertation
Language:German
Published: Philipps-Universität Marburg 2011
Innere Medizin
Subjects:
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. Zuppinger, C., F. Timolati, and T. Suter, 2007, Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.: Cardiovasc Toxicol, v. 7, p. 61-6.


2. Schenk, T., M. Enders, S. Pollak, R. Hahn, and D. Huzly, 2009, High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy.: J Clin Microbiol, v. 47, p. 106- 10.


3. Noutsias, M., B. Seeberg, H. Schultheiss, and U. Kühl, 1999, Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy.: Circulation, v. 99, p. 2124-31.


4. Mestroni, L., C. Rocco, D. Gregori, G. Sinagra, A. Di Lenarda, S. Miocic, M. Vatta, B. Pinamonti, F. Muntoni, A. L. Caforio, W. J. McKenna, A. Falaschi, M. Giacca, and Camerini, 1999b, Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group: J Am Coll


5. Kühl, U., D. Lassner, M. Pauschinger, U. Gross, B. Seeberg, M. Noutsias, W. Poller, and H. Schultheiss, 2008, Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy.: J Med Virol, v. 80, p. 1243-51.


6. Pankuweit, S., R. Moll, U. Baandrup, I. Portig, G. Hufnagel, and B. Maisch, 2003, Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens.: Hum Pathol, v. 34, p. 497-503.


7. Scheld, and M. Deng, 2001, Activation of the cardiac interleukin-6 system in advanced heart failure.: Eur J Heart Fail, v. 3, p. 415-21.


8. Baughman, 2000, Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.: N Engl J Med, v. 342, p. 690-5.


9. Papadogiannakis, N., T. Tolfvenstam, B. Fischler, O. Norbeck, and K. Broliden, 2002, Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant.: Clin Infect Dis, v. 35, p. 1027-31.


10. Kuethe, F., J. Lindner, K. Matschke, J. Wenzel, P. Norja, K. Ploetze, S. Schaal, V. Kamvissi, S. Bornstein, U. Schwanebeck, and S. Modrow, 2009, Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis.: Clin Infect Dis, v. 49, p. 1660-6.


11. Isaacs, A., and J. Lindemann, 1957, Virus interference. I. The interferon.: Proc R Soc Lond B Biol Sci, v. 147, p. 258-67.


12. Maisch, B., and L. Drude, 1991, Pericardioscopy--a new diagnostic tool in inflammatory diseases of the pericardium.: Eur Heart J, v. 12 Suppl D, p. 2-6.


13. Maisch, B., G. Hufnagel, U. Schönian, and C. Hengstenberg, 1995, The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID).


14. Regan, T., 1990, Alcohol and the cardiovascular system.: JAMA, v. 264, p. 377-81.


15. McNamara, D., R. Holubkov, R. Starling, G. Dec, E. Loh, G. Torre-Amione, A. Gass, K. Janosko, T. Tokarczyk, P. Kessler, D. Mann, and A. Feldman, 2001, Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.: Circulation, v. 103, p. 2254-9.


16. Kitabatake, M. Nagai, Y. Inaba, and H. Nakagawa, 2008, Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan.: Circ J, v. 72, p. 343-8.


17. Modrow, 2009, Adaptive immune responses against parvovirus B19 in patients with myocardial disease.: J Clin Virol, v. 44, p. 27-32.


18. Komajda, M., J. Jais, F. Reeves, B. Goldfarb, J. Bouhour, Y. Juillieres, J. Lanfranchi, P. Peycelon, P. Geslin, and D. Carrie, 1990, Factors predicting mortality in idiopathic dilated cardiomyopathy.: Eur Heart J, v. 11, p. 824-31.


19. Camerini, 1997, Epidemiology of dilated cardiomyopathy. A prospective post- mortem study of 5252 necropsies. The Heart Muscle Disease Study Group.: Eur Heart J, v. 18, p. 117-23.


20. Maisch, B., P. M. Seferović, A. D. Ristić, R. Erbel, R. Rienmüller, Y. Adler, W. Z. Tomkowski, G. Thiene, M. H. Yacoub, and T. F. o. t. D. a. M. o. P. D. o. t. E. S. o. Cardiology, 2004b, Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.: Eur Heart J, v. 25, p. 587-610.


21. Management of patients with suspected (peri-)myocarditis and inflammatory dilated cardiomyopathy.: Herz, v. 31, p. 881-90.


22. Maisch, B., I. Portig, A. Ristic, G. Hufnagel, and S. Pankuweit, 2000, Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report.: Herz, v. 25, p. 200-9.


23. Moon, 1995, A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.: N Engl J Med, v. 333, p. 269-75.


24. Liu, P., and J. Mason, 2001, Advances in the understanding of myocarditis.: Circulation, v. 104, p. 1076-82.


25. Anhang Anzahl 1049


26. Narula, J., N. Haider, R. Virmani, T. DiSalvo, F. Kolodgie, R. Hajjar, U. Schmidt, M. Semigran, G. Dec, and B. Khaw, 1996, Apoptosis in myocytes in end-stage heart failure.: N Engl J Med, v. 335, p. 1182-9.


27. Parrillo, J., R. Cunnion, S. Epstein, M. Parker, A. Suffredini, M. Brenner, G. Schaer, S. Palmeri, R. r. Cannon, and D. Alling, 1989, A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy.: N Engl J Med, v. 321, p. 1061-8.


28. Malone, S. Shah, and C. Vadheim, 1990, A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes.: N Engl J Med, v. 323, p. 1167-72.


29. van der Meché, F., and P. Schmitz, 1992, A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.: N Engl J Med, v. 326, p. 1123-9.


30. Kearney, J. Price, B. Rogers, G. Schauer, R. Chinnock, and J. Towbin, 1997, Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction.: Circulation, v. 96, p. 3549-54.


31. Yoshikawa, T., A. Baba, and Y. Nagatomo, 2009, Autoimmune mechanisms underlying dilated cardiomyopathy: Circ J, v. 73, p. 602-7.


32. Neu, N., N. R. Rose, K. W. Beisel, A. Herskowitz, G. Gurri-Glass, and S. W. Craig, 1987, Cardiac myosin induces myocarditis in genetically predisposed mice: J Immunol, v. 139, p. 3630-6.


33. Vogelsberg, P. Fritz, K. Klingel, R. Kandolf, and U. Sechtem, 2004, Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology.: Circulation, v. 109, p. 1250- 8.


34. Pankuweit, S., A. Richter, V. Ruppert, R. Funck, and B. Maisch, 2008, [Classification, genetic predisposition and risk factors for the development of cardiomyopathies]: Internist (Berl), v. 49, p. 441-2, 444-7.


35. Why, H., B. Meany, P. Richardson, E. Olsen, N. Bowles, L. Cunningham, C. Freeke, and L. Archard, 1994, Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy.: Circulation, v. 89, p. 2582-9.


36. Böhm, and U. Sechtem, 2010b, Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance.: Circulation, v. 122, p. 900-9.


37. Maekawa, Y., M. Ouzounian, M. Opavsky, and P. Liu, 2007, Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity.: Circulation, v. 115, p. 5-8.


38. Seidman, and J. Young, 2006, Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.: Circulation, v. 113, p. 1807-16.


39. Kaya, Z., M. Afanasyeva, Y. Wang, K. Dohmen, J. Schlichting, T. Tretter, D. Fairweather, V. Holers, and N. Rose, 2001, Contribution of the innate immune system to autoimmune myocarditis: a role for complement.: Nat Immunol, v. 2, p. 739-45.


40. Karras, A., L. Potier, A. Reboux, N. Coldea, L. Perdrix, C. Jacquot, and E. Mousseaux, 2010, Cryoglobulin-induced cardiomyopathy.: J Am Coll Cardiol, v. 55, p. e13.


41. Popma, J., R. Cigarroa, L. Buja, and L. Hillis, 1989, Diagnostic and prognostic utility of right-sided catheterization and endomyocardial biopsy in idiopathic dilated 6. Literaturverzeichnis 94 cardiomyopathy.: Am J Cardiol, v. 63, p. 955-8.


42. Shaw, T., P. Elliott, and W. McKenna, 2002, Dilated cardiomyopathy: a genetically heterogeneous disease.: Lancet, v. 360, p. 654-5.


43. Luk, A., E. Ahn, G. S. Soor, and J. Butany, 2009, Dilated cardiomyopathy: a review: J Clin Pathol, v. 62, p. 219-25.


44. RALES, 1996, Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]): Am J Cardiol, v. 78, p. 902-7.


45. Mills, R., and M. Lauer, 2004, Endomyocardial biopsy: a procedure in search of an indication.: Am Heart J, v. 147, p. 759-60.


46. Inaba, and Y. Ohno, 2004, Environmental factors and risk of idiopathic dilated cardiomyopathy: a multi-hospital case-control study in Japan.: Circ J, v. 68, p. 1011-7.


47. Spry, C., M. Take, and P. Tai, 1985, Eosinophilic disorders affecting the myocardium and endocardium: a review.: Heart Vessels Suppl, v. 1, p. 240-2.


48. Michels, V., T. Olson, F. Miller, K. Ballman, A. Rosales, and D. Driscoll, 2003, Frequency of development of idiopathic dilated cardiomyopathy among relatives of patients with idiopathic dilated cardiomyopathy.: Am J Cardiol, v. 91, p. 1389-92.


49. Kawai, C., 1999, From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future: Circulation, v. 99, p. 1091- 100.


50. Mestroni, L., B. Maisch, W. McKenna, K. Schwartz, P. Charron, C. Rocco, F. Tesson, A. Richter, A. Wilke, and M. Komajda, 1999a, Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy.: Eur Heart J, v. 20, p. 93-102.


51. Tschöpe, C., C. Bock, M. Kasner, M. Noutsias, D. Westermann, P. Schwimmbeck, M. Pauschinger, W. Poller, U. Kühl, R. Kandolf, and H. Schultheiss, 2005, High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction.: Circulation, v. 111, p. 879-86.


52. Kühl, U., M. Pauschinger, M. Noutsias, B. Seeberg, T. Bock, D. Lassner, W. Poller, R. Kandolf, and H. Schultheiss, 2005a, High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction.: Circulation, v. 111, p. 887-93.


53. Ramaraj, R., 2008, Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment.: Cardiol Rev, v. 16, p. 172-80.


54. Muller, J., G. Wallukat, M. Dandel, H. Bieda, K. Brandes, S. Spiegelsberger, E. Nissen, R. Kunze, and R. Hetzer, 2000, Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy: Circulation, v. 101, p. 385-91.


55. Kishimoto, C., N. Takamatsu, H. Kawamata, H. Shinohara, and H. Ochiai, 2000, Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change.: J Am Coll Cardiol, v. 36, p. 1979-84.


56. Liu, C., J. Chen, and K. Liu, 2005, Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials.: Int Heart J, v. 46, p. 113-22.


57. Takata, and Y. Doi, 2008, Improvement in prognosis of dilated cardiomyopathy in the elderly over the past 20 years: J Cardiol, v. 52, p. 111-7.


58. Imazio, M., E. Cecchi, B. Demichelis, S. Ierna, D. Demarie, A. Ghisio, F. Pomari, L. Coda, R. Belli, and R. Trinchero, 2007, Indicators of poor prognosis of acute pericarditis.: Circulation, v. 115, p. 2739-44.


59. Neumann, D., N. Rose, A. Ansari, and A. Herskowitz, 1994, Induction of multiple heart autoantibodies in mice with coxsackievirus B3-and cardiac myosin-induced autoimmune myocarditis.: J Immunol, v. 152, p. 343-50.


60. Maisch, B., A. Richter, A. Sandmöller, I. Portig, and S. Pankuweit, 2005, Inflammatory dilated cardiomyopathy (DCMI). Herz, v. 30, p. 535-44.


61. Zimmermann, O., C. Rodewald, M. Radermacher, M. Vetter, J. M. Wiehe, M. Bienek- Ziolkowski, V. Hombach, and J. Torzewski, 2010, Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?: J Card Fail, v. 16, p. 348-56.


62. Vignola, P., A. Bloch, A. Kaplan, H. Walker, P. Chiotellis, and G. Myers, 1977, Interobserver variability in echocardiography.: J Clin Ultrasound, v. 5, p. 238- 42.


63. Reuter, P. M., 2004, Komplikationen bei Endomyokardbiopsien. Eine Untersuchung vonca. 17800 Gewebeentnahmen von 1989 bis 1997, in M. Reuter, ed.


64. Literaturverzeichnis acute infection.: Clin Infect Dis, v. 41, p. 1201-3.


65. Xu, Q., S. Dewey, S. Nguyen, and A. V. Gomes, 2010, Malignant and benign mutations in familial cardiomyopathies: Insights into mutations linked to complex cardiovascular phenotypes: J Mol Cell Cardiol.


66. Starling, R., D. Van Fossen, D. Hammer, and D. Unverferth, 1991, Morbidity of endomyocardial biopsy in cardiomyopathy.: Am J Cardiol, v. 68, p. 133-6.


67. Smoot, M. Mullen, P. Woolf, E. Wigle, J. Seidman, and C. Seidman, 2000, Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.: N Engl J Med, v. 343, p. 1688-96.


68. Mason, J., 2003, Myocarditis and dilated cardiomyopathy: an inflammatory link.: Cardiovasc Res, v. 60, p. 5-10.


69. Magnani, J., and G. Dec, 2006, Myocarditis: current trends in diagnosis and treatment.: Circulation, v. 113, p. 876-90.


70. Rose, N., 2009, Myocarditis: Infection Versus Autoimmunity.: J Clin Immunol.


71. Imazio, M., and R. Trinchero, 2008, Myopericarditis: Etiology, management, and prognosis.: Int J Cardiol, v. 127, p. 17-26.


72. Smith, S., and P. Allen, 1991, Myosin-induced acute myocarditis is a T cell-mediated disease.: J Immunol, v. 147, p. 2141-7.


73. Maisch, B., and K. Karatolios, 2008, [New possibilities of diagnostics and therapy of pericarditis]: Internist (Berl), v. 49, p. 17-26.


74. Pankuweit, S., I. Portig, and B. Maisch, 2002, Pathophysiology of cardiac inflammation: molecular mechanisms: Herz, v. 27, p. 669-76.


75. Söderlund, M., R. von Essen, J. Haapasaari, U. Kiistala, O. Kiviluoto, and K. Hedman, 1997, Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy.: Lancet, v. 349, p. 1063-5.


76. van Rijckevorsel, G., G. Sonder, M. Schim van der Loeff, and J. van den Hoek, 2009, Population-based study on the seroprevalence of parvovirus B19 in Amsterdam.: J Med Virol, v. 81, p. 1305-9.


77. Wu, L., and L. Cooper, 2004, Potential of the right ventricular endomyocardial biopsy to diagnose and assist in the management of congestive heart failure: insights from recent clinical trials: Congest Heart Fail, v. 10, p. 133-9.


78. Rose, N., 2008, Predictors of autoimmune disease: autoantibodies and beyond.: Autoimmunity, v. 41, p. 419-28.


79. Lindinger, and M. Böhm, 2008, Predictors of outcome in patients with suspected


80. Sechtem, 2006, Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.: Circulation, v. 114, p. 1581-90.


81. S. Long, M. R. Bristow, P. Lavori, and L. Mestroni, 2007, Prevalence of desmin mutations in dilated cardiomyopathy: Circulation, v. 115, p. 1244-51.


82. Maron, B. J., J. M. Gardin, J. M. Flack, S. S. Gidding, T. T. Kurosaki, and D. E. Bild, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults: Circulation, v.


83. Pankuweit, S., I. Portig, H. Eckhardt, M. Crombach, G. Hufnagel, and B. Maisch, 2000, Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease: Herz, v. 25, p. 221-6.


84. Katritsis, D., P. Wilmshurst, J. Wendon, M. Davies, and M. Webb-Peploe, 1991, Primary restrictive cardiomyopathy: clinical and pathologic characteristics.: J Am Coll Cardiol, v. 18, p. 1230-5.


85. Wilczewski, T. Niklewski, M. Zembala, L. Polonski, M. Rozek, and J. Wodniecki, 2001, Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two- year follow-up results.: Circulation, v. 104, p. 39-45.


86. Olsen, G. Thiene, J. Goodwin, I. Gyarfas, I. Martin, and P. Nordet, 1996, Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.: Circulation, v. 93, p. 841-2.


87. WHO, 1980, Report of the WHO/ISFC task force on the definition and classification of


88. Magnani, J., H. Danik, G. J. Dec, and T. DiSalvo, 2006, Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors.: Am Heart J, v. 151, p. 463-70.


89. Mason, J. W., 1978, Techniques for right and left ventricular endomyocardial biopsy: Am J Cardiol, v. 41, p. 887-92.


90. Kasper, E., W. Agema, G. Hutchins, J. Deckers, J. Hare, and K. Baughman, 1994, The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients.: J Am Coll Cardiol, v. 23, p. 586-90.


91. Stouffer, G. A., R. G. Sheahan, D. J. Lenihan, and P. Patel, 2003, The current status of immune modulating therapy for myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin: Am J Med Sci, v. 326, p. 369-74.


92. Michels, V., P. Moll, F. Miller, A. Tajik, J. Chu, D. Driscoll, J. Burnett, R. Rodeheffer, J. Chesebro, and H. Tazelaar, 1992, The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy.: N Engl J Med, v. 326, p. 77-82.


93. Takada, H., C. Kishimoto, and Y. Hiraoka, 1995, Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti- inflammatory effects: Circulation, v. 92, p. 1604-11.


94. Maruhashi, S. Takeda, H. Nonogi, and T. Hashimoto, 2003, Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress.: Int J Cardiol, v. 91, p. 173-8.


95. Maisch, B., G. Hufnagel, S. Kölsch, R. Funck, A. Richter, H. Rupp, M. Herzum, and S. Pankuweit, 2004a, Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.: Herz, v. 29, p. 624-36.


96. Maisch, B., and S. Pankuweit, 2010, [Treatment of progressive heart failure: pharmacotherapy, resynchronization (CRT), surgery]: Herz, v. 35, p. 94-101.


97. Judge, D., 2009, Use of genetics in the clinical evaluation of cardiomyopathy.: JAMA, v. 302, p. 2471-6.


98. Weintrub, P., 1987, Uses of immune globulins in the prophylaxis and treatment of viral infections.: Clin Lab Med, v. 7, p. 897-910.


99. Woodruff, J., 1980, Viral myocarditis. A review.: Am J Pathol, v. 101, p. 425-84.


100. Yajima, T., and K. Knowlton, 2009, Viral myocarditis: from the perspective of the virus.: Circulation, v. 119, p. 2615-24.


101. Schultheiss, 2005b, Viral persistence in the myocardium is associated with progressive cardiac dysfunction.: Circulation, v. 112, p. 1965-70.


102. Robinson, J. L., L. Hartling, E. Crumley, B. Vandermeer, and T. P. Klassen, 2005, A systematic review of intravenous gamma globulin for therapy of acute myocarditis: BMC Cardiovasc Disord, v. 5, p. 12.


103. Vapalahti, A. Vaheri, M. Söderlund-Venermo, and K. Hedman, 2006, Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.: Proc Natl Acad Sci U S A, v. 103, p. 7450-3.


104. Matsumori, A., T. Yamada, H. Suzuki, Y. Matoba, and S. Sasayama, 1994, Increased circulating cytokines in patients with myocarditis and cardiomyopathy.: Br Heart J, v. 72, p. 561-6.


105. M. Slama, P. Steg, and D. Le Guludec, 2001, Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms.: J Am Coll Cardiol, v. 37, p. 786-92.


106. Noutsias, M., S. Pankuweit, and B. Maisch, 2009b, Pathophysiological mechanisms of parvovirus B19 infection.: J Clin Microbiol, v. 47, p. 2358-9; author reply 2359.


107. Sakakibara, S., and S. Konno, 1962, Endomyocardial biopsy.: Jpn Heart J, v. 3, p. 537- 43.


108. Fontaine, and F. Camerini, 1994, Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.: Br Heart J, v. 71, p. 215-8.


109. Hoher, V. Hombach, and J. Torzewski, 2005, Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy.: Int J Cardiol, v. 104, p. 92-100.